Arvinas Files 8-K for Jan 7 Event; Details Pending

TL;DR

**Arvinas filed an 8-K for a Jan 7 event, but the details are missing; watch for updates.**

AI Summary

Arvinas, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024. This filing is a standard 'Other Events' report, indicating that there's no specific major corporate action like an acquisition or earnings release, but rather a disclosure of information that the company deems important for investors. For shareholders, this means the company is maintaining transparency by reporting an event, though the filing itself doesn't detail the event, suggesting it might be a placeholder for future, more specific disclosures or a routine update.

Why It Matters

This filing signals that Arvinas, Inc. had an event on January 7, 2024, that it felt was important enough to disclose, even if the specific details aren't yet public. Investors should monitor for subsequent filings or announcements to understand the nature and impact of this 'Other Event'.

Risk Assessment

Risk Level: medium — The risk is medium because an 'Other Events' 8-K without specific details creates uncertainty about what event occurred and its potential impact on the company.

Analyst Insight

Investors should add Arvinas, Inc. to their watchlists and set alerts for subsequent filings or news releases to understand the nature of the 'Other Event' reported on January 7, 2024, before making any investment decisions.

Key Players & Entities

• Arvinas, Inc. (company) — the registrant filing the 8-K
• January 7, 2024 (date) — date of the earliest event reported
• January 8, 2024 (date) — date the 8-K was filed
• 001-38672 (string) — Commission File Number
• ARVN (string) — Trading Symbol for Common stock
• The Nasdaq Stock Market LLC (company) — exchange where Arvinas common stock is registered

Forward-Looking Statements

• Arvinas, Inc. will file a more detailed 8-K or press release explaining the 'Other Event'. (Arvinas, Inc.) — medium confidence, target: 2024-01-15

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share ARVN The Nasdaq Stock Market

Filing Documents

• arvn-20240107.htm (8-K) — 29KB
• 0001655759-24-000002.txt ( ) — 158KB
• arvn-20240107.xsd (EX-101.SCH) — 2KB
• arvn-20240107_lab.xml (EX-101.LAB) — 25KB
• arvn-20240107_pre.xml (EX-101.PRE) — 13KB
• arvn-20240107_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. The investigational new drug application submitted by Arvinas, Inc. (the "Company") for ARV-393, a PROTAC degrader designed to target the BCL6 protein, and the clinical trial application submitted by the Company for ARV-102, the Company's PROTAC degrader designed to target the LRRK2 protein, have been authorized by the U.S. Food and Drug Administration and European Medicines Agency, respectively. The Company plans to initiate first-in-human Phase 1 clinical trials for both ARV-393 and ARV-102 in the first half of 2024.

Forward-Looking Statements

Forward-Looking Statements. This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the potential plans related to and timing of clinical trials for ARV-393 and ARV-102. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company's strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The word "plan," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements the Company makes as a result of various risks and uncertainties, including the important factors discussed the important factors discussed in the "Risk Factors" sections contained in the Company's quarterly and annual reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this Current Report on Form 8-K reflect the Company's current views with respect to future events, and the Company assumes no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description of Exhibit 104 Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARVINAS, INC. Date: January 8, 2024 By: /s/ Sean Cassidy Sean Cassidy Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR